Comparative Pharmacology
Head-to-head clinical analysis: CLINDAMYCIN HYDROCHLORIDE versus LINCOMYCIN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLINDAMYCIN HYDROCHLORIDE versus LINCOMYCIN HYDROCHLORIDE.
CLINDAMYCIN HYDROCHLORIDE vs LINCOMYCIN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to the 50S ribosomal subunit, inhibiting peptide bond formation and bacterial protein synthesis.
Binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking peptide bond formation.
150-450 mg orally every 6 hours; maximum 1.8 g/day.
600 mg intramuscularly every 24 hours or 600 mg intravenously every 8 to 12 hours. Maximum dose: 8 g/day intravenously.
None Documented
None Documented
The terminal elimination half-life of clindamycin is approximately 2-3 hours in adults with normal renal and hepatic function. In patients with severe hepatic impairment, half-life is prolonged to 8-12 hours. Renal impairment does not significantly alter half-life.
5.4 ± 1.0 hours (normal renal function); prolonged in hepatic impairment (up to 14 hours) and anuria (up to 10 hours)
Approximately 10-20% of clindamycin is excreted unchanged in urine; the remainder is hepatically metabolized and excreted in bile and feces as inactive metabolites. Fecal excretion accounts for about 4% of an administered dose as active drug and 60-70% as metabolites. Renal clearance is minor.
Renal (40% unchanged), biliary/fecal (significant via enterohepatic circulation; ~30% in feces)
Category A/B
Category C
Lincosamide Antibiotic
Lincosamide Antibiotic